close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

51.61 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Dec 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Hims & Hers Health (HIMS) Surges After Hours on Robust Q3 and Renewed Novo Nordisk (NVO) Wegovy Talks
Hims & Hers Health (NYSE: HIMS) became a significant after-hours mover on Monday, November 3, 2025, following the release of its third-quarter 2025 financial results and the pivotal announcement of... 
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
Hims Says It's Negotiating A New Deal With Novo Nordisk; Shares Surge ↗
Hims & Hers Health said late Monday it's in discussions with Novo Nordisk to sell Wegovy shots. The news buoyed Hims stock. 
Via Investor's Business Daily
News headline image
Hims & Hers Stock Pops After Q3 Earnings: Here's Why ↗
Here's a look at the Q3 earnings report from Hims & Hers Health. 
Via Benzinga
News headline image
Did Novo Nordisk Just Say "Checkmate" to Pfizer? ↗
These two leading drugmakers are fighting over a promising GLP-1 candidate. 
Via The Motley Fool
Topics Intellectual Property
The Battle For Metsera Acquisition Heats Up As Pfizer Files A Second Lawsuit ↗
Via Stocktwits
Retail Investors Now Expect Viking Therapeutics To Bag A Deal After Novo Nordisk, Pfizer Engage In A Bidding War For Rival Metsera ↗
Via Stocktwits
Novo Nordisk Submits Revised Bid For Metsera, Enters A Bidding War With Pfizer ↗
Via Stocktwits
News headline image
Metsera Calls Pfizer's Claims 'Nonsense' In Latest Buyout Battle Salvo ↗
Metsera called Pfizer's claims "nonsense" in a follow-up Monday to Pfizer's lawsuit against Metsera and Novo Nordisk. 
Via Investor's Business Daily
Topics Economy Lawsuit
News headline image
Pfizer Accuses Novo Nordisk Of Antitrust Violations In Metsera Takeover Battle ↗
Pfizer sues Metsera and Novo Nordisk, alleging breach of contract and antitrust violations over a rival $9 billion bid challenging its $4.9 billion merger deal. 
Via Benzinga
Topics Lawsuit
News headline image
2 Beaten-Down Stocks That Could Be About to Rally ↗
It would be best to get in before the rest of the market pounces on these opportunities. 
Via The Motley Fool
News headline image
Novo Nordisk A/S (NYSE:NVO): A Top Dividend Stock with Strong Profitability and Financial Health ↗
Novo Nordisk (NVO) is a top dividend stock with a 3.6% yield, strong growth, and a sustainable payout backed by exceptional profitability and financial health. 
Via Chartmill
News headline image
Should You Buy Viking Therapeutics Before Nov. 5? ↗
Viking's stock surged in one trading session after a positive clinical trial report last year. 
Via The Motley Fool
News headline image
P/E Ratio Insights for Novo Nordisk ↗
 
Via Benzinga
News headline image
Is It Time to Dump Your Shares of Pfizer? ↗
Pfizer stock has dropped 50% over the past three years. 
Via The Motley Fool
Topics Intellectual Property
News headline image
AI Unleashes a New Era: Biopharma’s Accelerated Revolution and the Rise of TechBio
The biopharmaceutical industry is undergoing an immediate and profound transformation, as Artificial Intelligence (AI) rapidly compresses timelines, drastically reduces costs, and significantly... 
Via TokenRing AI
Topics Animal Testing Artificial Intelligence Economy
News headline image
Pfizer Sues Novo Nordisk And Metsera To Block The Proposed $6.5 Billion Deal ↗
Pfizer sued Metsera and Novo Nordisk on Friday to prevent Novo's proposed $6.5 billion takeover of the smaller company. 
Via Investor's Business Daily
Topics Law Enforcement Lawsuit
News headline image
Viking Therapeutics Stock Powers Toward Best Month Of The Year — Wall Street, Retail Bulls Fired Up On Obesity Drug Promise ↗
Traders on Stocktwits linked Novo Nordisk’s renewed bid for Metsera to competition from Viking’s obesity drug VK2735, fueling further optimism. 
Via Stocktwits
News headline image
Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain ↗
As Eli Lilly, Novo Nordisk, and Pfizer battle for dominance in the obesity-drug market, these ETFs are offering exposure to the GLP-1 gold rush. 
Via Benzinga
Topics ETFs
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Novo Nordisk Kicks Off Bloody Battle With Pfizer, Bidding $6.5 Billion On Metsera ↗
Novo Nordisk kicked off a battle with Pfizer on Thursday, making an unsolicited $6.5 billion bid for obesity-focused Metsera. 
Via Investor's Business Daily
Topics Economy Government
News headline image
Pfizer Blasts Novo Nordisk's $9 Billion Counteroffer For Metsera As 'Reckless' ↗
Novo Nordisk's $9 billion offer for Metsera challenges Pfizer's existing merger deal, prompting sharp criticism and potential legal action. 
Via Benzinga
News headline image
1 Incredible Reason to Buy Novo Nordisk Stock (NVO) in November -- or Sooner ↗
It offers compelling weight-loss drugs -- and a compelling stock price, too. 
Via The Motley Fool
News headline image
Novo Nordisk Shares Fell 5.6% After President Trump Commented on Future Price Cuts for Weight Loss Drugs. Should Investors Be Worried? ↗
It's not the end of the world for the drugmaker. 
Via The Motley Fool
Topics Government Intellectual Property
News headline image
If I Could Only Buy 2 Stocks in the Last Quarter of 2025, I'd Pick These ↗
These two have been neglected by Wall Street too much. 
Via The Motley Fool
News headline image
Healthcare Sector Navigates Volatile Waters as S&P 500 Closes: A Deep Dive into Key Market Drivers
As the closing bell rings on October 27, 2025, the S&P 500 Healthcare sector stands at a critical juncture, exhibiting the nuanced volatility that defines this essential yet complex segment of the... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
What Is 1 of the Best Pharmaceutical Stocks to Buy Now? ↗
This pharma giant is entering the rapidly expanding market for weight loss drugs. 
Via The Motley Fool
News headline image
Viking Therapeutics: High Risk, High Reward Play ↗
Via MarketBeat
News headline image
Options Corner: A Reliable Quant Signal Just Flashed Again For Pharma Giant Novo Nordisk ↗
While Novo Nordisk has been victimized by broader market pressure, NVO stock has just flashed a reliable quant signal for bullish traders. 
Via Benzinga
News headline image
Eccogene Eyes Hong Kong IPO With Experimental Weight-Loss Drug, AstraZeneca Partnership ↗
 
Via Benzinga
Topics Initial Public Offering
News headline image
Breakout Momentum Plays You Need to Know About ↗
Three stocks may draw the attention of momentum investors—QURE spiked in September, OMER in October, and SDST has almost 1,000% in upside potential. 
Via MarketBeat
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today